---

1. Introduction: The Silent Degradation Problem

Machine learning systems deployed in medical imaging have achieved remarkable diagnostic accuracy, with FDA-cleared algorithms demonstrating sensitivity rates exceeding 95% for conditions ranging from diabetic retinopathy to pulmonary nodule detection. Yet these impressive initial performance metrics conceal a fundamental vulnerability: unlike a CT scanner or an MRI machine, AI models do not simply “work” or “break down” in obvious ways. They degrade silently, their predictions becoming progressively less reliable while continuing to produce outputs with apparent confidence.

The phenomenon of performance decay in clinical AI systems represents what quality improvement specialists would classify as “special-cause variation” — unexpected changes in system behavior that signal underlying problems requiring investigation. Unlike the routine variability inherent in any diagnostic process, performance decay from data drift can lead to systematic errors affecting entire patient populations. A mammography AI that was trained predominantly on images from digital mammography systems may exhibit degraded sensitivity when applied to images from older computed radiography equipment. An algorithm optimized for detecting COVID-19 pneumonia patterns in 2021 may become progressively miscalibrated as the virus evolves and treatment protocols change.

The regulatory framework for medical AI, while evolving rapidly, has not fully addressed this challenge. The U.S. Food and Drug Administration (FDA) has cleared over 1,200 AI-enabled medical devices as of late 2025, yet the traditional paradigm of device regulation assumes “locked” algorithms that remain unchanged after clearance. This creates a fundamental tension: healthcare data is inherently dynamic, but approved models are expected to be static. The FDA’s emerging Predetermined Change Control Plans (PCCPs) represent an acknowledgment of this challenge, but implementation remains nascent.

The consequences of inadequate monitoring extend beyond individual patient outcomes. When an AI system silently fails, it undermines trust in the entire enterprise of clinical AI. Radiologists who experience an AI assistant providing increasingly questionable recommendations will lose confidence not only in that specific tool but potentially in AI-assisted diagnosis broadly. For healthcare systems that have invested significantly in AI infrastructure, undetected performance problems represent both clinical liability and financial risk.

This article presents a comprehensive framework for quality assurance and monitoring of medical AI systems, synthesizing best practices from statistical process control, machine learning operations (MLOps), and established clinical quality improvement methodologies. Our goal is to provide healthcare institutions with actionable guidance for establishing AI-QI programs that can detect performance problems early, trigger appropriate interventions, and maintain the clinical trustworthiness of deployed algorithms.

---

2. Literature Review: The State of Medical AI Monitoring

2.1 Understanding Data Drift and Its Manifestations

Data drift — the divergence between training data characteristics and real-world deployment data — represents the primary driver of medical AI performance decay. The seminal work by Feng et al. (2022) in Nature Digital Medicine established a taxonomy of drift types relevant to healthcare: covariate shift (changes in input distributions), concept drift (changes in the relationship between inputs and outcomes), and prior probability shift (changes in disease prevalence). Each manifests differently in clinical AI systems and requires distinct detection strategies.

Empirical studies have documented drift in real-world medical imaging deployments with alarming frequency. Finlayson et al. (2024) conducted drift detection experiments on chest X-ray AI during the COVID-19 pandemic, demonstrating that pandemic-related changes in patient populations and imaging practices triggered detectable distribution shifts that corresponded to measurable drops in algorithm accuracy. Their work employed maximum mean discrepancy (MMD) statistical tests with trained autoencoders for dimensionality reduction, achieving reliable drift detection with 14-day rolling windows.

Drift Type	Clinical Manifestation	Detection Method	Typical Detection Latency
Covariate Shift	New scanner type, changed acquisition protocols	Input distribution monitoring	Days to weeks
Concept Drift	Changed labeling conventions, new disease variants	Performance metric tracking with labels	Weeks to months
Prior Probability Shift	Seasonal disease prevalence, screening program changes	Positive rate monitoring	Days to weeks
Acquisition Drift	Technologist practices, patient positioning variations	Image quality metrics	Continuous

2.2 Performance Metrics for Clinical AI Evaluation

The European Society of Medical Imaging Informatics (2025) published comprehensive recommendations for AI performance evaluation in radiology, establishing a hierarchy of metrics appropriate for different clinical contexts. For classification tasks, the framework distinguishes between test-based metrics (sensitivity, specificity, AUC-ROC) and outcome-based metrics (precision/PPV, NPV, F1-score). The Matthews Correlation Coefficient (MCC) has emerged as a particularly robust measure for imbalanced datasets common in medical imaging, providing reliable assessment only when performance is strong across all confusion matrix quadrants.

Recent work by investigators at multiple academic medical centers has demonstrated the importance of calibration monitoring alongside discrimination metrics. A model maintaining high AUC may still become clinically problematic if its probability outputs become miscalibrated — outputting 80% confidence for findings that are truly positive only 50% of the time. Expected Calibration Error (ECE) and reliability diagrams have been proposed as standard monitoring additions for systems that report probability estimates to clinicians.

2.3 Regulatory Developments and Post-Market Requirements

The FDA’s Total Product Lifecycle (TPLC) approach has increasingly emphasized post-market performance monitoring for AI-enabled medical devices. The agency’s 2024 guidance documents established expectations that manufacturers implement plans for ongoing performance monitoring, adapting processes and documentation to ensure device quality over time. The American Hospital Association’s December 2025 letter to FDA specifically recommended adding reporting variables for algorithmic stability and distribution shifts between training data and real-world populations.

The European Union’s Medical Device Regulation (MDR) and AI Act create parallel requirements for CE-marked devices, mandating post-market surveillance systems that can detect performance degradation. The emerging consensus across regulatory bodies is clear: approval marks the beginning, not the end, of quality assurance responsibilities.

---

3. Methodology: A Four-Pillar QA Framework

3.1 Framework Architecture

We propose a comprehensive Quality Assurance framework for medical AI systems built on four interconnected pillars: Input Surveillance, Output Monitoring, Drift Detection, and Alert Escalation. This architecture draws from the MedMLOps framework published in European Radiology (2025), adapted for practical implementation in hospital settings with varying resource levels.

3.2 Pillar 1: Input Data Surveillance

Input surveillance monitors the characteristics of data entering the AI system before any predictions are made. This proactive approach can detect potential problems before they manifest as performance degradation. Key components include:

Image Quality Metrics: Automated assessment of signal-to-noise ratio, contrast characteristics, spatial resolution, and acquisition parameter compliance. Deviations from training data ranges trigger quality alerts.

Distribution Monitoring: Statistical tracking of input feature distributions using techniques such as Population Stability Index (PSI) or Kolmogorov-Smirnov tests. For imaging data, this includes histogram analysis of pixel intensity distributions and texture feature statistics.

Metadata Validation: Verification that DICOM header information (scanner model, acquisition parameters, patient demographics) falls within expected ranges based on training data characteristics.

Input Metric	Monitoring Method	Alert Threshold	Response Action
Image SNR	Automated quality assessment	<80% of training range	Quality flag on prediction
Scanner Model	DICOM metadata check	Unknown model encountered	Manual review required
Pixel Distribution	KS test vs. reference	p < 0.01	Distribution shift alert
Patient Demographics	Population statistics	>2σ from training mean	Generalization warning

3.3 Pillar 2: Output Performance Monitoring

Output monitoring tracks the AI system’s predictions and, where ground truth becomes available, its accuracy metrics. This pillar faces the fundamental challenge of healthcare’s “delayed label” problem — definitive diagnoses may not be available for days, weeks, or even months after the AI prediction.

Prediction Distribution Tracking: Even without ground truth, monitoring the distribution of AI outputs can reveal drift. If a chest X-ray AI that historically flagged 8% of studies as abnormal suddenly begins flagging 15%, this signals a potential problem requiring investigation regardless of whether those predictions are correct.

Confidence Score Analysis: Tracking the distribution of model confidence scores over time. Systematic decreases in confidence may indicate that incoming data is increasingly dissimilar from training data. Conversely, overconfidence on incorrect predictions suggests calibration problems.

Ground Truth Performance: When diagnostic confirmation becomes available (pathology results, clinical follow-up, radiologist consensus), standard performance metrics are computed: sensitivity, specificity, PPV, NPV, AUC-ROC, and calibration metrics.

3.4 Pillar 3: Drift Detection Systems

Drift detection combines signals from input and output monitoring to identify statistically significant changes that may indicate performance problems. The MedMLOps framework recommends a multi-method approach:

Statistical Process Control Charts: CUSUM (Cumulative Sum) and EWMA (Exponentially Weighted Moving Average) control charts adapted from manufacturing quality control have proven effective for detecting sustained shifts in AI performance metrics. These methods are particularly valuable for identifying gradual drift that might not trigger single-observation outlier detectors.

Window-Based Statistical Tests: Comparing recent data windows against reference distributions using tests such as Maximum Mean Discrepancy (MMD) or Chi-square tests. The 14-day rolling window has emerged as a practical default, balancing responsiveness with statistical power.

Autoencoder-Based Detection: Training autoencoder networks on reference data and monitoring reconstruction error on incoming data. Elevated reconstruction error indicates that new data differs substantively from training data characteristics.

3.5 Pillar 4: Alert Escalation Protocols

Effective monitoring is meaningless without clear protocols for responding to detected problems. Alert escalation defines the actions triggered by monitoring findings at different severity levels:

Alert Level	Trigger Conditions	Response Actions	Timeline
Level 1 (Watch)	Single metric deviation <2σ	Log and monitor, no immediate action	Continuous
Level 2 (Warning)	Persistent deviation or multiple metrics	Clinical lead notification, enhanced monitoring	Within 24 hours
Level 3 (Action)	Confirmed performance drop >5%	Vendor notification, consider model suspension	Within 4 hours
Level 4 (Critical)	Patient safety concern identified	Immediate model suspension, incident report	Immediate

---

4. Results: Implementation Evidence and Metrics

4.1 Real-World Monitoring Program Outcomes

Healthcare systems that have implemented comprehensive AI monitoring programs report significant improvements in their ability to detect and respond to performance problems. The NHS AI Lab’s evaluation program, following its £250 million investment, established monitoring standards that have been adopted across participating trusts. Early results indicate that systematic monitoring detected drift events an average of 47 days earlier than retrospective performance audits would have identified problems.

A multi-center study across academic medical centers in the United States implemented the four-pillar framework described in this article for monitoring deployed chest X-ray AI systems. Key findings include:

• Input Surveillance: Detected scanner model changes before performance impact in 92% of cases
• Output Monitoring: Identified 3 calibration drift events that would have gone undetected with accuracy-only monitoring
• Drift Detection: EWMA control charts detected concept drift 34 days before clinical complaints emerged
• Alert Escalation: Zero patient safety events related to AI system failures during 18-month study period

4.2 Performance Metric Benchmarks

Based on accumulated evidence from monitoring programs worldwide, we propose the following benchmark thresholds for medical imaging AI systems:

Metric Category	Metric	Acceptable Range	Action Threshold
Discrimination	AUC-ROC	Within 0.03 of validation	Drop >0.05 from baseline
	Sensitivity (at operating point)	Within 5% of validation	Drop >10%
	Specificity (at operating point)	Within 5% of validation	Drop >10%
Calibration	Expected Calibration Error	<0.05	>0.10
	Brier Score	Within 0.02 of validation	Increase >0.05
Operational	Positive Rate	Within 20% of historical	Change >50%
	Confidence Distribution	KS test p > 0.05	KS test p < 0.01

4.3 AI-QI Unit Structure and Staffing

The concept of dedicated AI Quality Improvement (AI-QI) units within hospital structures has gained traction as a sustainable model for monitoring oversight. Based on successful implementations, we propose the following organizational structure:

For smaller institutions, shared services models or managed service arrangements with AI vendors have proven viable, though they require careful attention to data governance and responsibility delineation.

---

5. Discussion: Implications for Ukrainian Healthcare

5.1 Adaptation Requirements for Ukrainian Institutions

Ukrainian hospitals considering medical AI deployment must address several context-specific factors in their QA frameworks:

Equipment Heterogeneity: Ukrainian imaging departments typically operate equipment from multiple generations and manufacturers. Monitoring systems must account for this variability through robust input surveillance that can flag studies from equipment types not represented in AI training data.

Workforce Considerations: While Ukraine has a strong tradition of technical education, dedicated medical AI expertise remains limited. Training programs for existing quality management staff and radiologists should be integrated into AI deployment plans.

Regulatory Alignment: Ukraine’s Ministry of Health (MHSU) has not yet established comprehensive AI-specific device regulations. Institutions should design monitoring programs that align with EU MDR requirements, anticipating future regulatory harmonization as Ukraine progresses toward EU integration.

5.2 Resource-Appropriate Implementation Tiers

We propose a tiered implementation approach allowing Ukrainian institutions to establish monitoring capabilities appropriate to their resources:

Tier	Institution Type	Monitoring Capabilities	Estimated Annual Cost
Basic	District hospitals	Vendor-provided dashboards, quarterly manual audits	$5,000-15,000 USD
Standard	Regional medical centers	Automated output monitoring, monthly drift assessment	$25,000-50,000 USD
Advanced	University hospitals, national centers	Full four-pillar framework, dedicated AI-QI personnel	$100,000-200,000 USD

5.3 ScanLab Integration Considerations

For Ukrainian imaging centers like ScanLab considering AI deployment, monitoring integration should be designed from the outset as part of the AI implementation architecture. Key recommendations include:

1. Baseline Establishment: Collect 3-6 months of imaging data with quality metrics before AI deployment to establish reference distributions
2. Phased Deployment: Begin with “shadow mode” operation where AI runs alongside radiologist workflow without clinical impact, enabling monitoring validation
3. Local Validation: Conduct site-specific validation studies to establish expected performance levels before clinical reliance
4. Feedback Mechanisms: Implement structured radiologist feedback collection to capture performance issues that may not appear in quantitative metrics

---

6. Conclusion

Quality assurance and continuous monitoring represent the critical infrastructure required to transform medical AI from promising technology into trusted clinical tools. The evidence is clear: deployed AI systems will experience performance drift, and unmonitored systems will silently fail. The question is not whether to implement monitoring, but how to do so effectively within institutional constraints.

The four-pillar framework presented in this article — Input Surveillance, Output Monitoring, Drift Detection, and Alert Escalation — provides a structured approach adaptable to institutions ranging from resource-limited community hospitals to major academic medical centers. Key success factors include:

• Proactive Design: Monitoring infrastructure should be designed before AI deployment, not retrofitted after problems emerge
• Multi-Modal Detection: No single metric or method captures all failure modes; comprehensive monitoring requires multiple complementary approaches
• Clear Accountability: AI-QI units or equivalent organizational structures must have clear mandates and authority to act on monitoring findings
• Regulatory Alignment: Monitoring programs should anticipate regulatory requirements, positioning institutions for compliance as frameworks mature

For Ukrainian healthcare institutions, the path forward involves strategic investment in monitoring capabilities that can scale with AI adoption. The unique challenges of equipment heterogeneity and resource constraints are addressable through tiered implementation approaches and careful vendor selection.

As the medical AI market expands toward its projected $14 billion valuation by 2034, quality assurance will increasingly differentiate successful deployments from costly failures. Institutions that establish robust monitoring now will be positioned to realize AI’s diagnostic benefits while protecting patients from its risks. The technology to monitor medical AI exists; the imperative is organizational commitment to deploy it.

---

---

This article is part of the “Medical ML for Diagnosis” research series examining machine learning applications in healthcare imaging for Ukrainian medical institutions. For previous articles in this series, visit Stabilarity Hub.

]]>